Sutro Biopharma, Inc. — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5dbc3d1b-ed0c-49ba-be19-847fee250f36/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $102.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-119873 |
| FY 2024 | $62.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038884 |
| FY 2023 | $153.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-035949 |
| FY 2022 | $67.8M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-010976 |
| FY 2021 | $61.9M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002312 |
| FY 2020 | $42.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-013945 |
| FY 2019 | $42.7M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010890 |
| FY 2018 | $38.4M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-010890 |
| FY 2017 | $51.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-20-010890 |
| FY 2016 | $59.7M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-010253 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Sutro Biopharma, Inc. — all facts · Net Income · Operating Income